1
|
Novel diamide derivatives: Synthesis, characterization, urease inhibition, antioxidant, antibacterial, and molecular docking studies. J Mol Struct 2022. [DOI: 10.1016/j.molstruc.2022.132932] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
2
|
Yuen ES, Trocóniz IF. Can pentylenetetrazole and maximal electroshock rodent seizure models quantitatively predict antiepileptic efficacy in humans? Seizure 2015; 24:21-7. [DOI: 10.1016/j.seizure.2014.11.006] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Revised: 11/12/2014] [Accepted: 11/17/2014] [Indexed: 10/24/2022] Open
|
3
|
Soyer Z, Akgul O, Tarikogullari AH, Calis U. Synthesis and anticonvulsant activity of some N-(benzoyl)glycinanilide derivatives. Med Chem Res 2013. [DOI: 10.1007/s00044-013-0474-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
|
5
|
Poupaert JH, Hamoir G, Barbeaux P, Lambert D, Hénichart JP. Anticonvulsant Activity of Some N-Phenylphthalimide Derivatives in Rats and Mice. J Pharm Pharmacol 2011. [DOI: 10.1111/j.2042-7158.1995.tb05741.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jacques H Poupaert
- School of Pharmacy, University of Louvain, Avenue E. Mounier 73, B-1200 Brussels
| | - Gaëtane Hamoir
- School of Pharmacy, University of Louvain, Avenue E. Mounier 73, B-1200 Brussels
| | - Philippe Barbeaux
- School of Pharmacy, University of Louvain, Avenue E. Mounier 73, B-1200 Brussels
| | - Didier Lambert
- School of Pharmacy, University of Louvain, Avenue E. Mounier 73, B-1200 Brussels
| | | |
Collapse
|
6
|
Dhanawat M, Das N, Shrivastava SK. Design, synthesis, anticonvulsant screening and 5HT 1A/2A receptor affinity of N(3)-substituted 2,4-imidazolidinediones and oxazolidinediones. Drug Discov Ther 2011; 5:227-37. [DOI: 10.5582/ddt.2011.v5.5.227] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Meenakshi Dhanawat
- Department of Pharmaceutics, Institute of Technology, Banaras Hindu University
| | - Nirupam Das
- Department of Pharmaceutics, Institute of Technology, Banaras Hindu University
| | | |
Collapse
|
7
|
Rodríguez F, Rozas I, Kaiser M, Brun R, Nguyen B, Wilson WD, García RN, Dardonville C. New Bis(2-aminoimidazoline) and Bisguanidine DNA Minor Groove Binders with Potent in Vivo Antitrypanosomal and Antiplasmodial Activity. J Med Chem 2008; 51:909-23. [DOI: 10.1021/jm7013088] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Fernando Rodríguez
- Centre for Synthesis and Chemical Biology, School of Chemistry, Trinity College Dublin, Dublin 2, Ireland, Swiss Tropical Institute, Socinstrasse, 57, CH-4002 Basel, Switzerland, Department of Chemistry, Georgia State University, Atlanta, Georgia 30303-3083, Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Av. Complutense s/n, E-28040 Madrid, Spain, and Instituto de Química Médica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| | - Isabel Rozas
- Centre for Synthesis and Chemical Biology, School of Chemistry, Trinity College Dublin, Dublin 2, Ireland, Swiss Tropical Institute, Socinstrasse, 57, CH-4002 Basel, Switzerland, Department of Chemistry, Georgia State University, Atlanta, Georgia 30303-3083, Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Av. Complutense s/n, E-28040 Madrid, Spain, and Instituto de Química Médica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| | - Marcel Kaiser
- Centre for Synthesis and Chemical Biology, School of Chemistry, Trinity College Dublin, Dublin 2, Ireland, Swiss Tropical Institute, Socinstrasse, 57, CH-4002 Basel, Switzerland, Department of Chemistry, Georgia State University, Atlanta, Georgia 30303-3083, Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Av. Complutense s/n, E-28040 Madrid, Spain, and Instituto de Química Médica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| | - Reto Brun
- Centre for Synthesis and Chemical Biology, School of Chemistry, Trinity College Dublin, Dublin 2, Ireland, Swiss Tropical Institute, Socinstrasse, 57, CH-4002 Basel, Switzerland, Department of Chemistry, Georgia State University, Atlanta, Georgia 30303-3083, Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Av. Complutense s/n, E-28040 Madrid, Spain, and Instituto de Química Médica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| | - Binh Nguyen
- Centre for Synthesis and Chemical Biology, School of Chemistry, Trinity College Dublin, Dublin 2, Ireland, Swiss Tropical Institute, Socinstrasse, 57, CH-4002 Basel, Switzerland, Department of Chemistry, Georgia State University, Atlanta, Georgia 30303-3083, Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Av. Complutense s/n, E-28040 Madrid, Spain, and Instituto de Química Médica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| | - W. David Wilson
- Centre for Synthesis and Chemical Biology, School of Chemistry, Trinity College Dublin, Dublin 2, Ireland, Swiss Tropical Institute, Socinstrasse, 57, CH-4002 Basel, Switzerland, Department of Chemistry, Georgia State University, Atlanta, Georgia 30303-3083, Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Av. Complutense s/n, E-28040 Madrid, Spain, and Instituto de Química Médica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| | - Rory Nelson García
- Centre for Synthesis and Chemical Biology, School of Chemistry, Trinity College Dublin, Dublin 2, Ireland, Swiss Tropical Institute, Socinstrasse, 57, CH-4002 Basel, Switzerland, Department of Chemistry, Georgia State University, Atlanta, Georgia 30303-3083, Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Av. Complutense s/n, E-28040 Madrid, Spain, and Instituto de Química Médica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| | - Christophe Dardonville
- Centre for Synthesis and Chemical Biology, School of Chemistry, Trinity College Dublin, Dublin 2, Ireland, Swiss Tropical Institute, Socinstrasse, 57, CH-4002 Basel, Switzerland, Department of Chemistry, Georgia State University, Atlanta, Georgia 30303-3083, Departamento de Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Av. Complutense s/n, E-28040 Madrid, Spain, and Instituto de Química Médica, CSIC, Juan de la Cierva 3, E-28006 Madrid, Spain
| |
Collapse
|
8
|
Structure–activity relationship of phenytoinergic antiepileptic drugs related to ameltolide. Med Chem Res 2007. [DOI: 10.1007/s00044-007-9016-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Yogeeswari P, Sriram D, Thirumurugan R, Raghavendran JV, Sudhan K, Pavana RK, Stables J. Discovery of N-(2,6-Dimethylphenyl)-Substituted Semicarbazones as Anticonvulsants: Hybrid Pharmacophore-Based Design. J Med Chem 2005; 48:6202-11. [PMID: 16190747 DOI: 10.1021/jm050283b] [Citation(s) in RCA: 112] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Epilepsy is the most common primary neurological disorder known. In the past decade, various aryl semicarbazones have been designed that were structurally dissimilar from many common anticonvulsants containing the dicarboximide function (CONRCO), which may contribute to toxic side effects. In the present work various N4-(2,6-dimethylphenyl) semicarbazones were designed as pharmacophore hybrids between the aryl semicarbazones and ameltolide. A three-dimensional four-point pharmacophore model was developed for anticonvulsants, and the title compounds were found to match with ralitoline. All of the compounds exhibited anticonvulsant activity in the maximal electroshock test when administered by both intraperitoneal and oral routes. Compound N1-(2,6-dimethylphenyl)-N4-(2-hydroxybenzaldehyde) semicarbazone (9) emerged as a prototype with wide spectrum anticonvulsant agent active in five models of seizure with no neurotoxicity and hepatotoxicity. Compound 9 increased the 4-aminobutyric acid (GABA) level by 118% and inhibited the GABA transaminase enzyme both in vitro and ex vivo.
Collapse
Affiliation(s)
- Perumal Yogeeswari
- Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani 333031, India.
| | | | | | | | | | | | | |
Collapse
|
10
|
Soyer Z, Kiliç FS, Erol K, Pabuçcuoğlu V. Synthesis and anticonvulsant activity of some ω-(1H-imidazol-1-yl)-N-phenylacetamide and propionamide derivatives. ACTA ACUST UNITED AC 2004; 59:595-600. [PMID: 15262528 DOI: 10.1016/j.farmac.2003.07.011] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2003] [Accepted: 07/30/2003] [Indexed: 11/16/2022]
Abstract
In this study, eight new omega-(1H-imidazol-1-yl)-N-phenylacetamide and propionamide derivatives having 2,6-dimethyl, 2,6-dichloro, 2-chloro-6-methyl and 2-isopropyl substitutions on N-phenyl ring were synthesized to evaluate anticonvulsant activity against maximal electroshock test. The most active compounds in the series were the derivatives bearing 2-isopropyl and 2,6-dimethyl substituents on N-phenyl ring.
Collapse
Affiliation(s)
- Zeynep Soyer
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, Bornova, Izmir 35100, Turkey
| | | | | | | |
Collapse
|
11
|
Ho B, Michael Crider A, Stables JP. Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores. Eur J Med Chem 2001; 36:265-86. [PMID: 11337105 DOI: 10.1016/s0223-5234(00)01206-x] [Citation(s) in RCA: 127] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Using N-(2,6-dimethyl)phenyl-2-piperidinecarboxamide (1) and N-(alpha-methylbenzyl)-2-piperidinecarboxamide (2) as structural leads, a variety of analogues were synthesised and evaluated for anticonvulsant activity in the MES test in mice. In the N-benzyl series, introduction of 3-Cl, 4-Cl, 3,4-Cl2, or 3-CF3 groups on the aromatic ring led to an increase in MES activity. Replacement of the alpha-methyl group by either i-Pr or benzyl groups enhanced MES activity with no increase in neurotoxicity. Substitution on the piperidine ring nitrogen led to a decrease in MES activity and neurotoxicity, while reduction of the amide carbonyl led to a complete loss of activity. Movement of the carboxamide group to either the 3- or 4-positions of the piperidine ring decreased MES activity and neurotoxicity. Incorporation of the piperidine ring into a tetrahydroisoquinoline or diazahydrinone nucleus led to increased neurotoxicity. In the N-(2,6-dimethyl)phenyl series, opening of the piperidine ring between the 1- and 6-positions gave the active norleucine derivative 75 (ED50=5.8 mgkg(-1), TD50 =36.4 mgkg(-1), PI=6.3). Replacement of the piperidine ring of 1 by cycloalkane (cyclohexane, cyclopentane, and cyclobutane) resulted in compounds with decreased MES activity and neurotoxicity, whereas replacement of the piperidine ring by a 4-pyridyl group led to a retention of MES activity with a comparable PI. Simplification of the 2-piperidinecarboxamide nucleus of 1 into a glycinecarboxamide nucleus led to about a six-fold decrease in MES activity. The 2,6-dimethylanilides were the most potent compounds in the MES test in each group of compounds evaluated, and compounds 50 and 75 should be useful leads in the development of agents for the treatment of tonic-clonic and partial seizures in man.
Collapse
Affiliation(s)
- B Ho
- Department of Basic Pharmaceutical Sciences, College of Pharmacy, The University of Louisiana at Monroe, Monroe, LA 71209-0470, USA
| | | | | |
Collapse
|
12
|
|
13
|
Vamecq J, Bac P, Herrenknecht C, Maurois P, Delcourt P, Stables JP. Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore. J Med Chem 2000; 43:1311-9. [PMID: 10753468 DOI: 10.1021/jm990068t] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A series of compounds including 4-amino (1), 3-amino (2), 4-nitro (3), 2-methyl-3-amino (4), 2-methyl-3-nitro (5), 2-methyl-4-amino (6), 2-methyl-4-nitro (7), 2-methyl-5-amino (8), 2-methyl-5-nitro (9), 2-methyl-6-amino (10), 2-methyl-6-nitro (11), 2,6-dimethyl (12), 2-methyl-3-carboxy (13), 2-methoxycarbonyl (14), 2-methyl-4-methoxy (15), 2,4-dimethoxy (16), 2-chloro-4-amino (17), and 2-chloro-4-nitro (18) N-phenyl substituents of phthalimide were evaluated along with N-[3-methyl-(2-pyridinyl)]phthalimide (19), N-(3-amino-2-methylphenyl)succinimide (20), and phenytoin for anticonvulsant and neurotoxic properties. Initial screening in the intraperitoneal (ip) maximal electroshock-induced seizure (MES) test and the subcutaneous pentylenetetrazol-induced seizure (scPtz) test in mice led to the selection of 1, 2, 4, 10, 12, 17, and 19 for oral MES evaluation in rats. The resultant ED(50) values for 4, 10, 17, and phenytoin were 8.0, 28.3, 5.7 and 29.8 mg/kg, respectively. In the batrachotoxin affinity assay, IC(50) values for 17 and phenytoin were 0.15 and 0.93 microM, respectively, and in the recently validated magnesium deficiency-dependent audiogenic seizure test, ED(50) values of 5.2 and 23 mg/kg were obtained for 17 and phenytoin, respectively. Electrophysiology studies on compound 17 point out its ability to (i) potentiate GABA-evoked current responses with a failure to directly activate the GABAA receptor and (ii) to affect, at 100 microM excitatory non NMDA, but not NMDA, receptors with a 25% block of kainate-evoked response. Electrophysiology measurements on voltage-gated sodium channels in N1E-115 neuroblastoma cells confirm voltage-dependent block of these channels by compound 17. In view of its interaction with multiple ion channels, one would predict that compound 17 might be active in a wide range of seizure models.
Collapse
Affiliation(s)
- J Vamecq
- INSERM/Neuropaediatrics Department, Hôpital Roger Salengro, CHU Lille, 2, Avenue Oscar Lembret, 59037 Lille, France
| | | | | | | | | | | |
Collapse
|
14
|
Vamecq J, Lambert D, Poupaert JH, Masereel B, Stables JP. Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. J Med Chem 1998; 41:3307-13. [PMID: 9719582 DOI: 10.1021/jm9608772] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Fifteen compounds related to ameltolide (LY 201116) were studied for (i) anticonvulsant potential in the maximal electroshock-induced seizures (MES) and the subcutaneous pentylenetetrazol (sc Ptz) tests in mice and rats and (ii) interactions with neuronal voltage-dependent sodium channels. Compounds were chosen ranging in anticonvulsant activity in mice from very active to inactive. The active compounds were defined as those protecting 50% of the animals at doses between 10 and 50 micromol/kg and inactive compounds as those protecting 50% of the animals at doses greater than 1 mmol/kg. The series studied included three N-(2,6-dimethylphenyl)benzamides (compounds 1, 2 (ameltolide), and 3), three N-(2,2,6, 6-tetramethyl)piperidinyl-4-benzamides (compounds 4, 5, 6), one phenylthiourea (compound 7), five N-(2,6-dimethylphenyl)phthalimides (compounds 8, 9, 10, 13, and 14), two N-phenylphthalimide derivatives (compounds 11 and 12), and one N-(2,2,6, 6-tetramethyl)piperidinyl-4-phthalimide (compound 15). Phenytoin (PHT) was employed as the reference prototype antiepileptic drug. After inital screening in mice, compounds 1, 2, 3, 5, 8, 9, 10, 13, and 14 were selected for further testing in rats. Anticonvulsant ED50s (effective doses in at least 50% of animals tested) of compounds in the MES test were determined in rats dosed orally and amounted to 52 (1), 135 (2), 284 (3), 231 (8), 131 (9), 25 (10), 369 (13), 354 (14), and 121 (PHT) micromol/kg, compound 5 presenting with an ED50 value higher than 650 micromol/kg. In our hands, the apparent IC50s (inhibitory concentrations 50) of compounds toward binding to rat brain synaptosomes of [3H]batrachotoxinin-A-20alpha-benzoate were 0.25 (1), 0.97 (2), 0.35 (3), 25.8 (5), 161.3 (8), 183.5 (9), 0.11 (10), 1.86 (13), 47.8 (14), and 0.86 (PHT) microM. The relationship between the activity in the MES test and the capacity to interact in vitro with neuronal voltage-dependent sodium channels and the fact that the IC50 values obtained in the in vitro test are close to the brain concentrations at which anticonvulsant activities are reported to occur for ameltolide strongly suggest that the anticonvulsant properties of most compounds tested could be a direct result of their interaction with the neuronal voltage-dependent sodium channel.
Collapse
Affiliation(s)
- J Vamecq
- INSERM/CHRU Lille, Domaine du Certia, 369 rue Jules Guesde, BP 39, 59651 Villeneuve d'Ascq Cedex, France
| | | | | | | | | |
Collapse
|
15
|
Kanyonyo MR, Poupaert JH, Lambert DM. Anticonvulsant profile of 4-amino-(2-methyl-4-aminophenyl)benzamide in mice and rats. PHARMACOLOGY & TOXICOLOGY 1998; 82:47-50. [PMID: 9527647 DOI: 10.1111/j.1600-0773.1998.tb01397.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
An original ameltolide analogue 4-amino-(2-methyl-4-aminophenyl)benzamide, in which a second amino group has been introduced, was synthesized and evaluated for anticonvulsant activity. After intraperitoneal administration to mice, 4-amino-(2-methyl-4-aminophenyl)benzamide was found active in the maximal electroshock seizure test and against the tonic seizures elicited either by bicuculline or 3-mercaptopropionic acid. 4-amino-(2-methyl-4-aminophenyl)benzamide (4A-2M4A-PB) gave anti maximal electroshock seizures ED50 of 63 micromol/kg (15.4 mg/kg) and a TD50 of 676 micromol/kg (163 mg/kg), yielding a PI of 10.7; the potency is similar to that of the 4-amino-(2-methyl-3-aminophenyl)phthalimide (4A-2M3A-PP), superior to that of 4-amino-(2,6-dimethylphenyl)phthalimide (4A-2,6-DMPP), close to that of phenytoin and carbamazepine and inferior to that of ameltolide. 4A-2M4A-PB with an ED50 of 41[28-60] micromol/kg (9.9 mg/kg) is as active after oral administration to rats as carbamazepine, more active than ameltolide, 4-A-2M3A-PP and phenytoin and slightly less active than the 4A-2,6-DMPP. The introduction of a second amino group on the substituted phenyl ring does not affect drastically the anticonvulsant potency after intraperitoneal administration to mice; moreover, it seems to enhance the activity after oral administration. 4A-2M4A-PB is a good candidate both for further pharmacokinetic studies and for the study of the precise mechanism of action.
Collapse
Affiliation(s)
- M R Kanyonyo
- Department of Pharmaceutical Sciences, Catholic University of Louvain, Bruxelles, Belgium
| | | | | |
Collapse
|
16
|
|
17
|
Diouf O, Bourhim M, Lambert DM, Poupaert JH, Stables JP, Vamecq J. Anticonvulsant and neurotoxicological properties of 4-amino-N-(2-ethylphenyl)benzamide, a potent ameltolide analogue. Biomed Pharmacother 1997; 51:131-6. [PMID: 9181049 DOI: 10.1016/s0753-3322(97)86911-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
A well documented study on the anticonvulsant properties of 4-amino-N-(2-ethylphenyl)benzamide (4-AEPB) is here provided. Initial screening in mice dosed intraperitoneally and rats dosed orally indicated that 4-AEPB is active against maximal electroshock-induced seizures (MES), but does not protect animals against subcutaneous pentylenetetrazole (sc Ptz)-induced seizures. Quantitative evaluation of anti-MES activity and neurotoxicity of 4-AEPB given intraperitoneally to mice provided ED50 and TD50 values amounting to 28.6 and 96.3 mumol/kg respectively, resulting in a protective index (PI = TD50/ED50) equal to 3.36. Further quantitative evaluation in rats dosed orally indicated that the respective ED50 and TD50 values for 4-AEPB were 29.8 and more than 1,530 mumol/kg, resulting in a very high PI value of over 51. Comparison anticonvulsant properties and neurotoxicity of 4-AEPB with those previously reported in the literature for two 4-aminobenzamide derivatives, 4-amino-N-(2,6-dimethylphenyl)benzamide (or ameltolide, an antiepileptic drug prototype developed by Eli Lilly), and phenytoin, underlines the value of 4-AEPB for future pharmacological development. In this perspective, an additional favorable element is represented by the ability of 4-AEPB to increase the seizure threshold in the intravenous Ptz seizure threshold test in mice dosed intraperitoneally. Molecular modeling studies show that the translocation of one carbon unit in the isomerization of the 2,6-dimethylphenyl moiety of ameltolide to the 2-ethylphenyl counterpart succeeds in maintaining the conformational low energy presentation adopted by ameltolide, providing clues as to why the 4-AEPB here described is an anticonvulsant agent derived from the 4-aminobenzamide pharmacophore platform as potent as ameltolide.
Collapse
Affiliation(s)
- O Diouf
- INSERM, Domaine du Certia, Villeneuve-d'Ascq, France
| | | | | | | | | | | |
Collapse
|
18
|
Bailleux V, Vallée L, Nuyts JP, Hamoir G, Poupaert JH, Stables JP, Vamecq J. Synthesis and anticonvulsant activity of some 4-nitro-N-phenylbenzamides. Eur J Med Chem 1995; 30:439-44. [DOI: 10.1016/0223-5234(96)88254-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/1994] [Accepted: 12/06/1994] [Indexed: 11/27/2022]
|
19
|
Kadaba PK, Morgan MM. Triazolines 31--anticonvulsant properties of three triazoline--and aziridinedicarboximide derivatives. Biomed Pharmacother 1995; 49:381. [PMID: 8562867 DOI: 10.1016/0753-3322(96)82669-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
|
20
|
Saxena AK, Saxena M. Developments in anticonvulsants. PROGRESS IN DRUG RESEARCH. FORTSCHRITTE DER ARZNEIMITTELFORSCHUNG. PROGRES DES RECHERCHES PHARMACEUTIQUES 1995; 44:185-291. [PMID: 7644666 DOI: 10.1007/978-3-0348-7161-7_6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- A K Saxena
- Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow, India
| | | |
Collapse
|
21
|
Borlak JT, Harsany V, Schneble H, Haegele KD. pNAT and CYP2D6 gene polymorphism in epileptic patients. Biochem Pharmacol 1994; 48:1717-20. [PMID: 7980640 DOI: 10.1016/0006-2952(94)90456-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Certain anticonvulsant drugs require N-acetylation as a major route of metabolic clearance. Single point mutations of the polymorphic N-acetyltransferase gene (pNAT) are the primary cause for impaired drug acetylation. Pharmacokinetic parameters are altered in slow acetylator phenotypes and this may compromise drug safety. Genetic analysis of allelic frequencies of individual pNAT genotypes point to significant increases in carriers of the S1/wt and S3/wt (P < 0.05) allele and a significant reduction in carriers of the S2/S2 (P < 0.01) allele, when control and epileptic patients are compared. Furthermore, the presumed link between the cytochrome P450 CYP2D6 polymorphism and the pathogenesis of Parkinson's disease led us to investigate, whether a similar relationship can be expected for other CNS disorders. Our findings indicate that poor metabolizers are more frequent (P < 0.05) amongst epileptic patients, when compared with a control population. An estimate of the odds ratio may suggest an increased risk [95% CI (confidence interval) 1.043-4.734] of up to 5-fold in epileptic patients carrying this mutation. This provides further evidence for a potential link between the debrisoquine hydroxylase gene polymorphism and CNS disorder and therefore warrants further study.
Collapse
Affiliation(s)
- J T Borlak
- Marion Merrell Dow Research Institute, Strasbourg, France
| | | | | | | |
Collapse
|
22
|
Bailleux V, Vallée L, Nuyts JP, Vamecq J. Anticonvulsant activity of some 4-amino-N-phenylphthalimides and N-(3-amino-2-methylphenyl)phthalimides. Biomed Pharmacother 1994; 48:95-101. [PMID: 7919112 DOI: 10.1016/0753-3322(94)90083-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
A series of fifteen N-phenylphthalimides including 12 4-amino-N-phenylphthalimides and three N-(3-amino-2-methylphenyl)phthalimides was prepared and evaluated for anticonvulsant properties. The compounds were tested against seizures induced by electroshock (MES) and pentylenetetrazol (scPTZ) in mice dosed intraperitoneally. Their neurologic toxicity was assessed using the rotorod assay procedure. The most potent 4-amino-N-phenylphthalimides against MES were those possessing small lipophilic groups in either 2 or 2 and 6 positions of the N-phenyl ring. They also exhibited some activity against scPTZ and were the most toxic of the series. By contrast, no activity against scPTZ or neurotoxicity could be observed up to 300 mg/kg for members of the N-(3-amino-2- methylphenyl)phthalimide series. In this series, the order of anti-MES activity appears to correspond to the phthalimide ring substitution pattern of 4-amino > H > 4-methyl. Quantitation of anticonvulsant properties and toxicity of 4-amino-N-(2,6-dimethylphenyl)phthalimide (ADD 213063) previously initiated in rats has been, here, extended to mice dosed intraperitoneally but also orally. The confrontation of the two modes of administration in mice suggests that ADD 213063 presents with a good bioavailability.
Collapse
Affiliation(s)
- V Bailleux
- North France Center for the Study of Childhood Epilepsy, Centre hospitalier Universitaire, Lille France
| | | | | | | |
Collapse
|
23
|
Bailleux V, Vallée L, Nuyts JP, Vamecq J. Original anticonvulsant properties of two N-phenylphthalimide derivatives. Biomed Pharmacother 1993; 47:463-4. [PMID: 8061248 DOI: 10.1016/0753-3322(93)90345-l] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Affiliation(s)
- V Bailleux
- North France Center for the Study of Childhood Epilepsy, Centre Hospitalier Universitaire, Lille, France
| | | | | | | |
Collapse
|
24
|
Abstract
The newly characterized anticonvulsant ameltolide was studied in mice in combination with the standard antiepileptic drugs (AEDs), phenytoin (PHT), carbamazepine (CBZ), and valproate (VPA). In combination with either PHT or CBZ, ameltolide produced dose-additive effects in the maximal electroshock (MES) test and in the horizontal screen (HS) test for neurologic impairment. The large separation between the doses for the anticonvulsant effects and the neurologically impairing effects (protective index, PI) were maintained as well in the combinations as in the individual compounds. VPA was impotent in the MES test and did not have a clear separation between the doses that produce the anticonvulsant effects and those that are neurologically impairing (low PI). When VPA and ameltolide were combined, the effects were less than additive by isobolographic analysis on both the MES and HS tests. At high oral doses (20 and 40 mg/kg, p.o.), ameltolide produced impairment on the HS test and decreased body temperature. The effects on the HS test were enhanced twofold, whereas the effects on body temperature were not markedly enhanced, by coadministration of the MES ED95 of PHT and CBZ. VPA (MES ED95) appeared to antagonize the temperature-lowering effects of ameltolide. These interaction studies suggest that ameltolide would be safe, with no unexpected effects, when used in epileptic patients concurrently receiving these standard AEDs. These studies also suggest that the effects of ameltolide would be lessened by simultaneous administration of VPA.
Collapse
Affiliation(s)
- J D Leander
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285
| |
Collapse
|
25
|
Leander JD, Parli CJ, Potts B, Lodge D. Relation of plasma and brain concentrations of the anticonvulsant ameltolide to its pharmacologic effects. Epilepsia 1992; 33:696-704. [PMID: 1628587 DOI: 10.1111/j.1528-1157.1992.tb02350.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Ameltolide, a newly described anticonvulsant, was studied to determine the relation between dose administered, plasma and brain concentrations, and pharmacologic effects. The relation of the N-acetyl metabolite and the OH-N-acetyl metabolite to the dose administered and to the pharmacologic effects was also determined. Ameltolide plasma concentrations in both mice and rats were linearly related to dose administered over the entire dose range from low doses, at which the anticonvulsant effects were noted, to high doses, at which neurologic impairment occurred. The plasma concentrations of the metabolites were not as consistently linearly dose-related in the two species. In rats, the brain concentrations of ameltolide were highly correlated with plasma concentrations and the doses administered. Ameltolide was shown to have a phenytoin (PHT)-like anticonvulsant profile in vitro in the cortical slice preparation. These data confirm the potent anticonvulsant profile of ameltolide and the lack of significant activity of the metabolites.
Collapse
Affiliation(s)
- J D Leander
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285
| | | | | | | |
Collapse
|
26
|
Higdon GL, McKinley ER, Markham JK. Ameltolide. I: Developmental toxicology studies of a novel anticonvulsant. TERATOLOGY 1991; 44:37-44. [PMID: 1957261 DOI: 10.1002/tera.1420440107] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Ameltolide, a novel anticonvulsant agent, has been shown in animal models to be effective in controlling seizures. The developmental toxicity of ameltolide was evaluated in two species. Naturally mated rats and rabbits were dosed once daily by gavage on gestation days (GD) 6-17 and 6-18, respectively. Rats were given doses of 0, 10, 25, or 50 mg/kg; rabbits were given 0, 25, 50, or 100 mg/kg. Laparotomy was performed on rats on GD 20 and on rabbits on GD 28. In rats, maternal toxicity was indicated at the 25- and 50-mg/kg dose levels by depressed body weight gain. Fetal body weight was depressed at the 50-mg/kg dose level. Fetal viability and morphology were not affected. The no-observed effect levels (NOEL) for adult and developmental toxicity in the rat were 10 and 25 mg/kg, respectively. In rabbits, maternal toxicity was indicated by a net loss in body weight at the 50- and 100-mg/kg dose levels. Fetal viability and body weight were depressed at the 100 mg/kg dose level. Shortened digits occurred on the right forepaw of one fetus at the 50-mg/kg dose level (in conjunction with severe maternal toxicity) and on the hindpaws of two fetuses from separate litters at the 100-mg/kg dose level. Incomplete ossification of the phalanges occurred on the forepaws of nine fetuses from four litters at the 100-mg/kg dose level. Ameltolide was weakly teratogenic in the rabbit. The NOEL for adult and developmental toxicity in the rabbit was 25 mg/kg.
Collapse
Affiliation(s)
- G L Higdon
- Toxicology Research Laboratories, Eli Lilly and Co., Greenfield, Indiana 46140
| | | | | |
Collapse
|
27
|
Pohland RC, Vavrek MT. Ameltolide. II: Placental transfer of radiocarbon following the oral administration of a novel anticonvulsant in rats. TERATOLOGY 1991; 44:45-9. [PMID: 1957262 DOI: 10.1002/tera.1420440108] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The placental transfer of orally administered ameltolide was evaluated to confirm embryonic exposure in the rat developmental toxicity study (Higdon et al., '91). Dissection techniques were used to determine the amount of total radiocarbon that traversed the placenta and distributed within the embryo in pregnant CD rats 0.75, 2, 5, 12, and 24 h after a single oral gavage dose of 50 mg/kg [14C]ameltolide on gestation day 12. Quantification of radiocarbon within placental and embryonic tissues and amniotic fluid was determined and compared with maternal plasma, liver, kidney, uterus, and ovary. Highest concentrations of radiocarbon occurred at 5 h postdose in all tissues sampled (maternal and embryonic) and then declined steadily over the 24-h time course of the study. Maternal liver contained the highest concentrations of radiocarbon at all time points and peaked at 5.86% of dose at 5 h. Embryonic tissues accounted for less than 0.2% of the administered dose at all time points. Tissue-to-maternal plasma ratios indicated that maternal liver and kidney concentrations were higher than maternal plasma concentrations at all time points. Uterine and ovarian concentrations were approximately equal to maternal plasma concentrations at 5, 12, and 24 h postdose. Although placental, embryonic, and amniotic fluid tissue-to-maternal plasma ratios were less than or equal to 1.0, ratios increased slightly throughout the time course of this study. Results from this study confirm embryonic exposure to radiocarbon associated with [14C]ameltolide and/or its metabolites in the rat developmental toxicity study, which has demonstrated the lack of observable teratogenic effects.
Collapse
Affiliation(s)
- R C Pohland
- Toxicology Research Laboratories, Eli Lilly and Company, Greenfield, Indiana 46140
| | | |
Collapse
|
28
|
Stark LG, Albertson TE. The effects of LY-201116 [4-amino-N-(2,6-dimethylphenyl) benzamide] on the amygdala-kindled rat. Neuropharmacology 1990; 29:1085-9. [PMID: 2087258 DOI: 10.1016/0028-3908(90)90117-a] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The effects of LY-201116, a 4-aminobenzamide, were examined in rats using the amygdala kindling model, both during acquisition of the kindled response and in fully kindled animals. Dose-response and time-response studies for efficacy and rotorod toxicity were completed following intraperitoneal injection of the drug. Afterdischarge duration, behavioral seizure response, kindled seizure threshold and EEG recordings were used to assess efficacy and toxicity of the drug. In the acquisition trial, the drug (7.5 mg/Kg) did not significantly alter the number of stimulations required to produce the first stage 5 kindled response nor did it modify afterdischarge durations. Doses of 11.25 and 15 mg/Kg suppressed afterdischarge and diminished behavioral responses significantly in fully kindled rats, but these doses were also neurotoxic as judged by rotorod performance. The non-selective anticonvulsant effect of 11.25 mg/Kg lasted at least 90 min. A dose of 15 mg/Kg raised kindled seizure threshold and diminished afterdischarge duration. Doses of 20, 30 and 40 mg/Kg produced spontaneous EEG spikes and seizures accompanied by behavioral convulsions. The drug thus exhibited non-selective anticonvulsant effects in fully kindled rats following doses of 11.25 or 15 mg/Kg, but exhibited proconvulsant activity following doses in the range of 20-40 mg/Kg.
Collapse
Affiliation(s)
- L G Stark
- Department of Medical Pharmacology and Toxicology, School of Medicine, University of California, Davis 95616
| | | |
Collapse
|
29
|
Clark CR, McMillian CL. Comparative anticonvulsant activity of 4-chlorobenzenesulfonamide and prototype antiepileptic drugs in rodents. Epilepsia 1990; 31:474-9. [PMID: 2114972 DOI: 10.1111/j.1528-1157.1990.tb05505.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The anticonvulsant and toxic properties of 4-chlorobenzenesulfonamide (ADD 55051) were compared with phenytoin (PHT), phenobarbital (PB), ethosuximide (ESM), and valproate (VPA). These compounds were evaluated in mice and rats using well-standardized anti-convulsant test procedures. The results indicate that ADD 55051 is a very effective anticonvulsant in the maximal electroshock seizure (MES) model in mice after either intraperitoneal (i.p.) or oral administration and in rats after oral administration. In mice treated i.p. or orally, ADD 55051 was also effective in preventing seizures induced by pentylenetetrazol (PTZ). The toxicity of ADD 55051 after oral administration was quite low, yielding high TD50 values in both mice and rats and producing a very high protective index (PI = TD50/ED50) in both species as compared with the prototype antiepileptic drugs (AEDs).
Collapse
Affiliation(s)
- C R Clark
- Department of Pharmacal Sciences, Auburn University School of Pharmacy, AL 36849
| | | |
Collapse
|
30
|
Abstract
A number of anticonvulsant drugs were studied for their efficacy in preventing seizures and death from intoxication with cocaine. Rats were first pretreated with the test drug then subjected to large doses of intraperitoneally administered cocaine. In this model, control animals developed seizures in approximately 6 min, followed by death in approximately 10 min. Statistically significant protection against seizures and death was afforded by pretreatment with diazepam, phenobarbitol and the blocker of the uptake of gamma-aminobutyric acid (GABA), SKF 100330A. Only partial protection was afforded by the N-methyl-d-aspartate (NMDA) antagonist MK 801, the benzodiazepine antagonist, flumazenil and the novel aminobenzamide, LY 201116. Valproic acid and phenytoin demonstrated limited efficacy against cocaine-induced seizures, without consistently reducing death. Carbamazepine and ethosuximide did not significantly reduce seizures or death. In this model of acute cocaine toxicity, the anticonvulsants diazepam, phenobarbital and the blocker of the uptake of GABA, SKF 100330A were the most effective in protecting rats from cocaine-induced seizures and death. These data offer insight into future approaches for the treatment of patients with the acute toxic effects of cocaine.
Collapse
Affiliation(s)
- R W Derlet
- Department of Internal Medicine, University of California, Davis
| | | |
Collapse
|
31
|
Abstract
A series of mono-, di-, and trimethylated derivatives of 4-chloro- and 4-methoxybenzanilide was synthesized and evaluated for anticonvulsant activity. This series was prepared in the course of studies designed to examine the relationship between anticonvulsant effects and benzamide structure. The compounds were tested in mice against seizures induced by maximal electroshock (MES) and pentylenetetrazole (scMet), as well as with the rotorod assay for neurologic deficit. In mice dosed intraperitoneally, 4-methoxy-2, 6-dimethylbenzanilide (4) showed a median anticonvulsant potency (ED50) of 18.58 mg/kg in the MES test and a median toxicity (TD50) of 133.72 mg/kg in the rotorod toxicity assay, yielding a protective index (PI = TD50/ED50) of 7.2. In mice dosed orally with 4, the anti-MES ED50 was 27.40 mg/kg and the TD50 dose was determined to be 342.58 mg/kg, resulting in a protective index of 12.5.
Collapse
Affiliation(s)
- C R Clark
- School of Pharmacy, Department of Pharmacal Sciences, Auburn University, AL 36849
| | | |
Collapse
|
32
|
Robertson DW, Lawson RR, Rathbun RC, Leander JD. Pharmacology of LY201409, a potent benzamide anticonvulsant. Epilepsia 1988; 29:760-9. [PMID: 3191892 DOI: 10.1111/j.1528-1157.1988.tb04232.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
LY201116 [4-amino-N-(2,6-dimethylphenyl)benzamide], an effective anticonvulsant in several animal models, is rapidly metabolized by N-acetylation in rats, mice and monkeys. In an attempt to preclude metabolic N-acetylation sterically, we investigated LY201409, an analogue possessing two methyl groups ortho to the 4-amino substituent. This structural modification successfully altered the metabolic pathway, and LY201409 displayed potent anticonvulsant activity. LY201409 antagonized maximal electroshock (MES)-induced seizures with ED50 values of 16.2 and 4.2 mg/kg after oral administration to mice and rats, respectively. The compound did not effectively antagonize seizures induced by a variety of chemical convulsants in rats, but did block pentylenetetrazol-induced seizures in mice. Thus, among the classic anticonvulsants, the profile of phenytoin most closely resembles that of LY201409. Studies conducted with the rotorod and horizontal screen assays in mice and behavioral studies in rats suggested that doses of LY201409 that produced CNS side-effects such as sedation or ataxia were well separated from the anti-MES doses. LY201409 was a potent, dose-dependent potentiator of hexobarbital-induced sleeping time in mice. Oral administration of 6.0 mg/kg led to a 372% increase in sleep time relative to control values. Although LY201409 is a potent and effective anticonvulsant, it is also one of the most potent potentiators of hexobarbital-induced sleep time yet described.
Collapse
Affiliation(s)
- D W Robertson
- Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285
| | | | | | | |
Collapse
|
33
|
Clark CR. Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyl)benzamide and prototype antiepileptic drugs in mice and rats. Epilepsia 1988; 29:198-203. [PMID: 2832143 DOI: 10.1111/j.1528-1157.1988.tb04420.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The anticonvulsant and toxic properties of 4-amino-N-(2,6-dimethylphenyl)benzamide, (ADD 75073), were compared with phenytoin (PHT), phenobarbital (PB), ethosuximide (ESM), and valproate (VPA). These compounds were evaluated in mice and rats using well-standardized anticonvulsant test procedures. The results indicate that ADD 75073 is a very potent anticonvulsant in the maximal electroshock seizure (MES) model. The compound was effective in nontoxic doses following intraperitoneal (i.p.) administration in mice and oral administration in both mice and rats. In mice, the i.p. administration of ADD 75073 resulted in an ED50 value of 2.6 mg/kg as compared with a value of 9.5 mg/kg for phenytoin (PHT) in the same assay. Compound ADD 75073 was ineffective in nontoxic doses against all other seizure models examined in this study, and thus has a pharmacologic profile similar to that of PHT.
Collapse
Affiliation(s)
- C R Clark
- Department of Pharmacal Sciences, School of Pharmacy, Auburn University, Alabama 36849
| |
Collapse
|
34
|
Abstract
A series of 4-aminophenylacetamides was prepared and evaluated for anticonvulsant activity. These compounds were prepared during studies designed to determine the relationship between benzamide-like compounds and anticonvulsant effects. Unlike benzamides, these phenylacetamides have a methylene group between the aromatic ring and the amide carbonyl. Consequently, formal conjugation is lost, and the number of conformational degrees of freedom has increased. The compounds were tested in mice against seizures induced by electroshock and pentylenetetrazol, and in the rotorod assay for neurologic deficit. The more active and selective anticonvulsants prepared in this study were those having an additional aromatic ring as part of the substituent on the amide nitrogen. Compound 16, the 4-aminophenylacetamide derived from 2,6-dimethylaniline, was the most potent compound observed (ED50 = 50.50 mg/kg against electroshock-induced convulsions and ED50 = 93.20 mg/kg against pentylenetetrazol-induced convulsions).
Collapse
|